Project WISH (Advancing Reproductive Health: Qualitative Methods & Interdisciplinary Mentorship)
This project is a naturalistic observational study of how women use sexual and reproductive health products, specifically sexual lubricants or contraceptive methods. The goal is to understand how women use (or not) each type of product over time, what they might do to alter their behavior or to alter the product so that the product can “fit” into their lives in such a way that they use (or do not use) the product effectively. The goal is to understand use/non-use and to use that understanding to help product developers and health care providers develop better sexual and reproductive health products.
Principal Investigator: Kathleen M. Morrow, PhD
Co-Investigators: Iris Tong, Melanie Hill, Sara Vargas, Robert Berry, and the Project WISH research team
Funding Agency: NICHD
Project DRUM (Development and Evaluation of Dual Compartment Combination Microbicides)
This project is a formative set of studies designed to gather information about the experience of using vaginal and rectal products for the prevention of HIV and other sexually transmitted diseases. It is part of a larger study where Dr Morrow collaborates with product developers to design effective prevention products. Dr. Morrow’s team works with study participants to evaluate different placebo products that vary in their design, in an effort to understand what users feel when they use the products and how those sensations and experience impact their willingness to use the products in the future. Unqiue to this study is the development of products that can be used both rectally and vaginally.
Co-Investigators: Rochelle Rosen, Joseph Fava, Sara Vargas, E Milu Kojic, and the Project DRUM research team; along with Robert Buckheit (ImQuest, PI), Anthony Ham (ImQuest), David Katz (Duke Univ) and co-investigators of the parent-U19 award
Funding Agency: NIAID
The FAB Project (Combination HIV prevention in drug-eluting fibers: designing for efficacy and use)
This project is a preclinical biomedical prevention technology development study that aims to design and preclinically evaluate a multi-agent HIV prevention product that is delivered using a novel technology called “drug-eluting fibers.” The fibers can be “woven” to create different devices/formulations to deliver the drugs into the vaginal environment, where the fibers dissolve and release the drug. Dr. Morrow’s team will determine the best formulation prototypes to move forward in development, as a function of an iterative user-centered approach to drug design.
Co-Investigators: Rochelle Rosen, Joseph Fava, Sara Vargas, and the FAB Project research team; along with Kim Woodrow (Univ of Washington, PI) and co-investigators of the parent PIP-R01